Key facts
- It has raised $14.9M across 1 recorded rounds; the latest was Early Stage VC ($9.3M) in May 2024.
- Notable investors include Johnson & Johnson JJDC, Johnson & Johnson, Rimonci Capital, SunMed Capital, Yonjin Venture.
- TECLens has filed 2 Form Ds with the SEC since 2024, most recently Mar 2025 ($9.3M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for TECLens
Funding rounds
1 roundsAbout TECLens
Developer of ophthalmic medical technology designed to provide non-invasive vision correction treatments. The company develops quantitative corneal cross-linking technology and related devices that use controlled ultraviolet light to strengthen and reshape the cornea, enabling clinicians to address refractive errors such as presbyopia and potentially treat conditions including hyperopia, myopia, and keratoconus through in-office procedures.
- Sector
- Healthcare
- HQ
- Stamford, CT, United States
- Founded
- 2013
- Employees
- 6
- Website
- teclens.com/
- Ownership
- Privately Held (backing)
TECLens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TECLens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TECLens in its N-PORT filings yet. We sweep new filings monthly.